(Reuters) – Corbus Pharmaceuticals Holdings Inc’s experimental drug for cystic fibrosis, a rare lung-scarring disease, could be a real money spinner and pose a challenge to rival Vertex Pharmaceuticals Inc’s successful treatment, Kalydeco. Corbus, a tiny biopharmaceutical company, received $5 million from the Cystic Fibrosis Foundation last month to develop the drug, Resunab, and expects […]

(Reuters) – Patients with type-2 diabetes who are overweight but not obese outlive diabetics of normal weight, scientists reported on Monday, in another example of the “obesity paradox.” Although public health officials issue dire warnings about the consequences of overweight, and employers are pressuring workers to slim down via “wellness programs,” the relationship between weight […]

WHIPPANY, N.J., May 4, 2015 /PRNewswire/ — Bayer HealthCare (Bayer) has entered into an exclusive license agreement with Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) on ISIS-FXIRx, an antisense investigational drug in clinical development for the prevention of thrombosis. Under the agreement Bayer will further develop and commercialize ISIS-FXIRx in areas of high unmet medical need. As […]

DOYLESTOWN, Pa., May 4, 2015 /PRNewswire/ — Makindus, Inc. a specialty pharmaceutical development company focused on ophthalmology announced today that the European Medicines Agency (EMA) has granted orphan drug designation for their lead candidate, MI-100, for the treatment of Stargardt’s Disease. “We are extremely pleased to now have orphan drug designation for MI-100 to treat Stargardt’s […]

At the recent American Association of Cancer Research (AACR) meeting, one of the most encouraging sets of presentations pertained to PARP inhibitors. What’s emerging is that this new class of drugs, once considered of limited benefit and primarily for cancer patients with BRCA mutations, offers a wide range of anti-tumor activity. In December 2014, the […]

GENEVA, May 4, 2015 /PRNewswire/ — EspeRare today announced that the European Medicines Agency (EMA) has granted an Orphan Drug Designation (ODD) for rimeporide, its lead compound for the treatment of Duchenne muscular dystrophy (DMD). DMD is a rare, life-threatening disease affecting boys early in childhood that causes muscle weakness and muscle loss. It is […]

ALMERE, the Netherlands, May 1, 2015 /PRNewswire/ — The scientific research company Emotional Brain is developing two on-demand medicines (i.e. to be taken when desired) for Female Sexual Interest/Arousal Disorder (FSIAD), considered by many as an unmet medical need. Recently Emotional Brain had positive and productive meetings with the U.S. Food & Drug Administration (FDA) […]

(Reuters Health) – Strength training might help prevent tension headaches, or at least reduce their pain, according to a small Danish study. Researchers found that neck and shoulder muscles were up to 26 percent weaker in people with regular tension headaches, compared to those without. They also saw strength imbalances between sets of muscles that […]

“We produced a mutant enzyme that is very efficient at cutting off the sugars in A and B blood, and is much more proficient at removing the subtypes of the A-antigen that the parent enzyme struggles with,” said David Kwan, the lead author of the study and a postdoctoral fellow in the Department of Chemistry. […]

(Reuters Health) – Residents of low-income neighborhoods with few high school graduates may be more likely to die after lung cancer surgery than more affluent patients, a U.S. study finds.   Researchers reviewed records for more than 200,000 patients who had lung cancer surgery from 2003 to 2011. They found that while factors such as […]